Cleopatra Hospitals stock falls 2.55 percent as profit drops

Cleopatra Hospitals stock (ISIN EGS729J1C018) was last at EGP 15.64 on the Egyptian Exchange on October 6, 2026, down 2.55 percent during the session. The market capitalization stood at EGP 22.76 billion, while the latest half-year figures show sharply different trends for revenue and earnings.

Revenue grows as earnings fall

MarketScreener reported on September 6, 2026, that Cleopatra Hospitals posted first-half 2026 sales of EGP 4.3092 billion, compared with EGP 3.3821 billion in the same period of 2025. That represents revenue growth of 27.4 percent.

The earnings picture moved in the opposite direction. Net income for the six months ended June 30, 2026, was EGP 270.7 million, down from EGP 451.0 million a year earlier, a decline of 40.0 percent. Second-quarter sales reached EGP 2.3367 billion versus EGP 1.7635 billion, while quarterly net income was EGP 152.6 million compared with EGP 250.4 million.

Analysts see limited upside

The valuation debate is centered on a five-analyst consensus. Stock Analysis lists a Hold consensus and an average 12-month price target of EGP 17.48, with the target 11.8 percent above the October 6 price of EGP 15.64.

The same consensus page reports trailing revenue of EGP 8.15 billion and net income of EGP 489.52 million over the last 12 months. It also lists a trailing price-to-earnings ratio of 47.02, leaving earnings delivery as the central counterweight to the company's top-line expansion.

Stock remains below yearly peak

Cleopatra Hospitals stock is valued at EGP 22.76 billion on October 6, 2026. The October 6 session price of EGP 15.64 places the stock below the EGP 19.72 52-week high cited by Decypha on September 30, 2026, while the company's addition to the EGX 30 was reported for September 1, 2026, by MarketScreener.

More news and analyses on Cleopatra Hospitals stock